A research study of how a new medicine called amycretin, given as tablets, works in Japanese men with obesity

Investigation of safety, tolerability and pharmacokinetic properties of multiple doses of oral NNC0487-0111 in Japanese participants with obesity(NN9487-5022)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2071230058

Enrollment

Registered

2023-09-05

Start date

2023-09-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

-28-day screening period -10-day intervention period, 10 once-daily oral administrations of 1, 3, 6 mg NNC0487-5022 or placebo tablets -3-week follow-up period

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: -Male with both parents of Japanese descent -Body mass index (BMI) between 25.0 and 34.9 kg/m2 (both inclusive). Body weight >=65.0 kg -Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator

Exclusion criteria

Exclusion criteria: -Any disorder that in the opinion from investigators might jeopardise participants safety or compliance with the protocol -Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator

Design outcomes

Primary

Measure	Time frame
To investigate the safety and tolerability of NNC0487-0111 after 10 once-daily oral administrations of tablets in Japanese participants with obesity	—

Secondary

Measure	Time frame
To investigate the pharmacokinetic properties of NNC0487-0111 after 10 once-daily oral administrations of tablets in Japanese participants with obesity	—

Contacts

Public ContactYuki Sudoh

Novo Nordisk Pharma Ltd.

jphc_clinical_trials@novonordisk.com+81-362661000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026